Retirement Systems of Alabama Has $2.05 Million Holdings in Sarepta Therapeutics, Inc. $SRPT

Retirement Systems of Alabama lifted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 3.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 120,118 shares of the biotechnology company’s stock after buying an additional 3,859 shares during the period. Retirement Systems of Alabama’s holdings in Sarepta Therapeutics were worth $2,054,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of SRPT. Cambridge Investment Research Advisors Inc. grew its position in Sarepta Therapeutics by 5.9% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 6,387 shares of the biotechnology company’s stock worth $408,000 after acquiring an additional 358 shares during the last quarter. Linden Thomas Advisory Services LLC grew its position in Sarepta Therapeutics by 5.6% during the 1st quarter. Linden Thomas Advisory Services LLC now owns 11,809 shares of the biotechnology company’s stock worth $754,000 after acquiring an additional 625 shares during the last quarter. Arcadia Investment Management Corp MI grew its position in Sarepta Therapeutics by 12.7% during the 1st quarter. Arcadia Investment Management Corp MI now owns 7,815 shares of the biotechnology company’s stock worth $499,000 after acquiring an additional 880 shares during the last quarter. State of Michigan Retirement System grew its position in Sarepta Therapeutics by 1.3% during the 1st quarter. State of Michigan Retirement System now owns 22,900 shares of the biotechnology company’s stock worth $1,461,000 after acquiring an additional 300 shares during the last quarter. Finally, Xponance Inc. grew its position in Sarepta Therapeutics by 3.2% during the 1st quarter. Xponance Inc. now owns 19,321 shares of the biotechnology company’s stock worth $1,233,000 after acquiring an additional 608 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Stock Performance

SRPT opened at $18.67 on Thursday. The business’s 50-day moving average price is $20.33 and its two-hundred day moving average price is $26.23. Sarepta Therapeutics, Inc. has a 1 year low of $10.41 and a 1 year high of $138.81. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -21.46 and a beta of 0.52. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.89 and a quick ratio of 1.81.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.15). Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The firm had revenue of $399.36 million during the quarter, compared to analyst estimates of $331.51 million. During the same period in the prior year, the business earned $0.62 EPS. The business’s revenue for the quarter was down 14.5% compared to the same quarter last year. Equities analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on SRPT. Baird R W lowered Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 18th. Mizuho upgraded Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $19.00 to $26.00 in a research report on Wednesday. Wells Fargo & Company decreased their price objective on Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday. Citigroup began coverage on Sarepta Therapeutics in a research report on Tuesday, July 22nd. They issued a “sell” rating on the stock. Finally, Jefferies Financial Group decreased their price objective on Sarepta Therapeutics from $40.00 to $35.00 and set a “buy” rating on the stock in a research report on Thursday, July 24th. Eight investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and six have assigned a Sell rating to the company’s stock. According to MarketBeat, Sarepta Therapeutics currently has an average rating of “Hold” and a consensus target price of $33.75.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.